Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world. AMD presents in two different types - "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula. Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will test the safety and efficacy of Squalamine in the treatment of AMD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
140
Florida Eye Microsurgical Institute
Boynton Beach, Florida, United States
Retina Health Center
Fort Meyers, Florida, United States
Bascom Palmer Eye Institute
Miami, Florida, United States
Midwest Eye Institute
To evaluate the safety profile of squalamine lactate at doses ranging from 40 mg to 160 mg of squalamine lactate
To evaluate short-term effects on best corrected visual acuity and changes in subretinal CNV as measured by optical coherence tomography
To evaluate short-term effects on best corrected visual acuity and changes in subretinal CNV as measured by fluorescein angiography
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Indianapolis, Indiana, United States
Retina Specialists
Towson, Maryland, United States
Eye Foundation of Kansas City
Kansas City, Missouri, United States
Ophthalmic Consultants of Long Island
Long Island City, New York, United States
Retina Associates of Western New York
Rochester, New York, United States
Charles Garcia, MD, P.A.
Houston, Texas, United States